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Over the past decades, some scientific progress has been made in understanding and treating cancer-related fatigue (CRF). 
However, three major problems have limited further progress: lack of agreement about measurement, inadequate understanding 
of the underlying biology, and problems in the conduct of clinical trials for CRF. This commentary reports the recommendations 
of a National Cancer Institute Clinical Trials Planning Meeting and an ongoing National Cancer Institute working group to address 
these problems so that high-priority research and clinical trials can be conducted to advance the science of CRF and its treatment. 
Recommendations to address measurement issues included revising the current case definition to reflect more rigorous criteria, 
adopting the Patient Reported Outcomes Measurement Information System fatigue scales as standard measures of CRF, and 
linking legacy measures to the scales. With regard to the biology of CRF, the group identified the need for longitudinal research 
to examine biobehavioral mechanisms underlying CRF and testing mechanistic hypotheses within the context of intervention 
research. To address clinical trial issues, recommendations included using only placebo-controlled trial designs. setting eligibility 
to minimize sample heterogeneity or enable subgroup analysis, establishing a CRF severity threshold for participation in clinical 
trials, conducting dissemination trials of efficacious interventions (such as exercise), and combining nonpharmacologic and phar-
macologic interventions to exploit the potential synergy between these approaches. Accomplishing these goals has the potential 
to advance the science of CRF and improve the clinical management of this troubling symptom.
J Natl Cancer Inst;2013;105:1432–1440
Introduction
Over the past decades, we have made progress in our understand-
ing of cancer-related fatigue (CRF) including its definition, meas-
urement in adults and children (1,2), and identification of a few 
effective therapies (3–11). Recent research has also explored bio-
markers and causal mechanisms of CRF. Despite this progress, 
there has been considerable diversity in the conceptual and opera-
tional definition of CRF limiting the generalizability of research 
findings; incomplete understanding of its biologic basis resulting in 
few pharmacologic targets for treatment; and limited clinical dis-
semination of efficacious behavioral interventions such as exercise.
the Clinical trials Planning meeting
The National Cancer Institute convened a Clinical Trials Planning 
Meeting (CTPM) on CRF in 2010 to examine the issues and 
initiate a process for developing a focused agenda to advance 
the science of symptom management in the community setting. 
Participants included representatives of academia, community 
oncology, government, the pharmaceutical industry, and the patient 
community. The overall goal of the CTPM was to set priorities 
for clinical trial investigations of CRF and make recommendations 
for high-priority research over the next several years. Objectives of 
the meeting were to 1) examine what is known about the biologic, 
psychological, and social factors related to fatigue and propose 
new studies to uncover the biopsychosocial mechanisms of CRF; 
2)  synthesize “lessons learned” from randomized clinical trials of 
CRF as a basis for setting new directions for clinical intervention 
research; 3)  review the definition and measurement of CRF 
(patient-reported, case definition, and biomarker measures); and 
4) explore clinical trial design and analysis issues in CRF research. 
These activities were directed to the development of a research 
agenda that builds on current knowledge and provides directions 
for future research. The CTPM spawned a working group that 
has continued the discussion. This commentary incorporates both 
the issues and recommendations of the CTPM and the updated 
consensus of the ongoing working group.
Background
Fatigue is the most common symptom experienced by adults and 
children with cancer (12–18). It can be associated with the cancer 
itself, cancer treatment, and/or other symptoms such as depression 
or poor sleep. CRF is a complex multidimensional problem char-
acterized by reduced energy and increased need for rest unrelated 
to recent sleep or activity that is known to affect quality of life 
adversely by reducing mental and physical functioning, disturb-
ing mood, and interfering with usual activities (16,19). CRF is also 
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emerging as a dose-limiting toxicity associated with established and 
newer therapies including targeted agents (such as tyrosine kinase 
inhibitors) that can ultimately limit the effectiveness of treatment 
(20). CRF is not always easily differentiated from everyday fatigue 
without careful diagnostic evaluation.
The true prevalence of CRF is unknown because differences in 
measurement yield a wide range of prevalence estimates depend-
ing on the domains of fatigue considered (21). For example, stud-
ies that simply ask about self-reported fatigue presence or severity 
have yielded prevalence estimates in the range of 70–99% (22). 
Studies requiring fatigue to exceed a threshold of severity, duration, 
or functional impairment have produced estimates in the 30–70% 
range (23). When CRF has been defined as a syndrome with spe-
cific diagnostic criteria inclusive of severity, functional impairment, 
and duration, prevalence estimates have been considerably lower, 
in the range of 15–30% (24,25).
CRF has been documented before the initiation of treatment 
(26), during cancer therapy (27–29), in disease-free survivors 
(24,30), and at the end of life (13,31,32). Patterns of fatigue dur-
ing treatment have varied with context. A  cyclic pattern of CRF 
has been documented with each cycle of chemotherapy followed 
by a gradual decline after completion of treatment (33,34). During 
radiotherapy, CRF follows a gradually increasing pattern until the 
end of treatment with a gradual decline after completion (27,35). 
Chronic fatigue has been documented in some disease-free sur-
vivors and in most individuals at the end of life (13,24,36). CRF 
has been associated with a variety of comorbid problems including 
sleep disturbance, psychiatric disturbances such as depression or 
anxiety, unrelieved pain, medication side effects, nutritional imbal-
ance, physical inactivity, and certain coping styles (25,27,37–40).
Causal mechanisms of CRF are not well understood. Recent 
evidence suggests that inflammatory processes, dysfunction of the 
hypothalamic-pituitary-adrenal (HPA) axis, disruption of circadian 
rhythms, and disturbance of monoamine pathways that regulate 
serotonin, dopamine, and norepinephrine may cause or contribute 
to CRF (41–47). However, CRF is known to be rooted in both 
biology and behavior, so a simple biological or psychosocial expla-
nation is unlikely; rather, the presence of biopsychosocial causal 
mechanisms is more likely. Because of the number and complexity 
of factors that could contribute to CRF, a model is provided as an 
organizational framework (Figure 1).
Definition and measurement of  
Cancer-related Fatigue
Conceptual Definition
The NCCN conceptual definition of CRF is widely endorsed and 
cited: CRF is “a distressing, persistent, subjective sense of physical, 
emotional and/or cognitive tiredness or exhaustion related to can-
cer or cancer treatment that is not proportional to recent activity 
and interferes with usual functioning” (21). Furthermore, subjec-
tive experience in these domains must interfere with functioning. 
The clarity of this conceptual definition and its general acceptance 
are congruent with the full case definition of CRF.
Case Definition
A conceptual definition alone lacks the specificity to diagnose a 
clinical case of CRF because threshold criteria including type, 
number, severity, and chronicity are not clearly articulated. To 
identify a case of CRF, one must determine whether a symptom of 
tiredness must be present across all three functional (physical, emo-
tional, and cognitive) domains or whether one domain only (eg, 
physical) is sufficient (Table 1). Likewise, it is important to decide 
how severe the fatigue must be and for what period of time it must 
be present. To address these limitations, a set of diagnostic crite-
ria to define CRF was proposed by the Fatigue Coalition (48) and 
recognized for inclusion in the International Classification of Diseases 
and Related Problems, 10th edition (49,50).
This CRF case definition requires the presence of fatigue and/
or related sensations and a specific number of related symptoms, 
evidence of impact on functioning, and inclusion/exclusion criteria 
(Table 1) (24,25,31,36,49,50,51–54). However, this case definition 
Figure 1. Correlates of cancer-related fatigue. HPA axis = hypothalamic-pituitary-adrenal axis.
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could benefit from further revision and validation including speci-
fication in the A1 criterion of “significant fatigue” in a specific time 
frame such as “most of the day and nearly every day.” The “B” 
criterion might benefit from a statement that “fatigue and asso-
ciated symptoms” are causing distress, as well as specification of 
the duration and pervasiveness of the impairment due to fatigue. 
Finally, the “D” criterion needs to be clarified to indicate when a 
psychiatric disorder is permitted and when it is not. In the context 
of a depressive disorder, a concurrent diagnosis of CRF might be 
considered only if the fatigue is pervasive and disabling, consistent 
with the suggested revisions of A1 and B criteria. Although the cur-
rent case definition provides a good starting point, further valida-
tion of the CRF criteria is recommended to set a rigorous standard 
for classifying CRF cases (24,25,36,54, 55).
Self-Report Measures of Cancer-Related Fatigue
As a subjective symptom, CRF is measured most efficiently via 
self-report. Numerous reviews of valid and reliable self-report 
measures for adults are appropriate for clinical research (1,56–58). 
Several reliable and valid instruments are available to evaluate 
fatigue in children with cancer including two validated proxy 
report instruments (parent and clinician) (2,59–62). Consistent 
with the conceptual definition, most self-report scales address both 
the sensation and impact domains of CRF (21), and some scales 
include additional domains such as reduced motivation, energy or 
vitality, or diurnal variation (1). Variability in the outcome domains 
assessed by self-report CRF measures has hindered meaningful 
comparison across studies and the translation of results into clinical 
practice.
Patient Reported Outcomes Measurement Information 
System as a Common Metric
Recent developments in the measurement of patient-reported 
outcomes have focused on the establishment of so-called item 
banks that consist of a large number of patient-reported outcomes 
 questions/items that have undergone extensive qualitative and 
quantitative evaluation to support their validity and reliability. All 
items in the item bank are calibrated on a common metric using 
item response theory models to allow comparison of scores from 
different item sets within the same item bank. In other words, a 
fatigue item bank allows the development of multiple fatigue 
short forms that can be targeted to the needs of any clinical trial. 
Fatigue scores from the short forms can be compared or combined 
across multiple studies (63–66). Recognizing the importance of 
patient-reported outcomes item banks, the National Institutes of 
Health launched the Patient Reported Outcome Measurement 
Information System (PROMIS) initiative to develop a publicly 
available set of standardized self-report measures of symptoms and 
other health domains including both pediatric and adult measures 
of fatigue (64). The adult PROMIS item bank includes 95 items, 
54 of which were retained in a cancer-specific application, measur-
ing an individual’s fatigue experience and the impact of fatigue on 
daily living. The pediatric PROMIS item bank includes 23 items 
measuring key domains of energy and capacity for physical func-
tioning, psychosocial effects, and anemia-specific concerns. The 
pediatric PROMIS fatigue measure also differentiates between 8- 
to 18-year-olds who are on treatment or in survivorship (67,68).
The adult PROMIS fatigue measure has been validated with 
fatigue measures commonly used in research (referred to as 
“legacy” scales) including the 13-item Functional Assessment of 
Chronic Illness Therapy-Fatigue and the 4-item SF-36 Vitality 
Scale (69,70). The PROMIS fatigue measure was found to be highly 
correlated with the legacy measures, and PROMIS scores statisti-
cally significantly differentiated cancer survivors at different points 
of the care continuum and different stages of disease. In addition, 
the PROMIS measure differentiated individuals with different 
 levels of performance status using the rating scale developed by the 
Eastern Cooperative Oncology Group (71,72). Demographic cor-
relates of PROMIS fatigue in the US general population included 
sex (women more than men), marital status (married more than 
unmarried), and age (younger more than older) (65). Race/ethnicity 
was also collected, and the PROMIS fatigue measure did not show 
differential item function by race (non-Hispanic whites, African 
Americans, Hispanics), but more analyses need to be conducted.
Table 1. Proposed International Classification of Disease-10 (ICD-10) criteria for diagnosis of cancer-related fatigue*
A Six or more of the following symptoms have been present every day or nearly every day during the same 2-week period in the past 
month and at least one of the symptoms is (A1) significant fatigue.
A1 Significant fatigue, diminished energy, or increased need to rest, disproportionate to any recent change in activity level
A2 Complaints of generalized weakness or limb heaviness
A3 Diminished concentration or attention
A4 Decreased motivation or interest to engage in usual activities
A5 Insomnia or hypersomnia
A6 Experience of sleep as unrefreshing or nonrestorative
A7 Perceived need to struggle to overcome inactivity
A8 Marked emotional reactivity (e.g., sadness, frustration, or irritability) to feeling fatigued
A9 Difficulty completing daily tasks attributed to feeling fatigued
A10 Perceived problems with short-term memory
A11 Post-exertional malaise lasting several hours
B The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
C There is evidence from the history, physical examination, or laboratory findings that the symptoms are a consequence of cancer or 
cancer therapy
D The symptoms are not primarily a consequence of comorbid psychiatric disorders such as major depression, somatization disorder, 
somatoform disorder, or delirium
* Reproduced from Cella et al (48) with permission from the American Society of Clinical Oncology [1998 draft (49)].
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Future studies are planned to estimate minimally important dif-
ferences (MIDs) for the pediatric and adult PROMIS measures. 
An MID is defined as the minimal change in fatigue level that is 
perceived by patients or clinicians as meaningful. Different from 
statistical significance, the MID can serve as a clinically meaningful 
indicator of the safety or efficacy of an intervention (73). The MID 
has been addressed in advanced cancer with varied results depend-
ing on the approach used to estimate the MID (73).
A potential benefit of PROMIS is that it offers an opportunity 
to link legacy CRF measures such as the Functional Assessment 
of Chronic Illness Therapy-Fatigue to the PROMIS fatigue 
measure and vice versa. This would enable comparisons across 
research results (74). Linking other legacy measures with PROMIS 
is encouraged. This reconciliation process could be especially 
beneficial in pediatrics that relies on age-specific measures. Children 
as young as 7 years of age can describe CRF in simple terms such 
as activity and lifestyle limitations; older school-age children can 
describe it in greater detail (75,76). Adolescents describe CRF with 
more abstract detail highlighting mental tiredness and physical 
fatigue (59,67). As a child moves from one age group to another, 
different forms of developmentally appropriate CRF measures 
that have been reconciled could be used to allow for longitudinal 
comparisons across different time points. Efforts are underway to 
validate common items between pediatric and adult CRF with a 
goal of developing a life span fatigue item bank.
recommendations
 • Update and revise the current case definition of CRF to reflect a 
more rigorous and specific description of the criteria.
 • Adopt the PROMIS Fatigue item banks and their short forms 
(pediatric and adult) as standard measures of CRF severity and 
impact.
 • Identify and take opportunities to link legacy CRF measures 
with PROMIS fatigue measures.
 • Examine the validity of the PROMIS-Fatigue item bank in 
predicting behavioral outcomes such as work performance for 
adults and school performance for children.
 • Examine differences in CRF levels by race/ethnicity.
 • Evaluate minimally important differences in CRF for different 
clinical groups.
the Biology of CrF
To date, CRF has been understood largely as a subjective patient-
reported experience, limiting our knowledge of its pathophysiol-
ogy. Research has shown that biologic mechanisms are involved in 
a broad range of psychosocial and behavioral sequelae including 
CRF. However, the precise physiologic pathways involved in the 
development of CRF and its relationship to the cancer experience 
are poorly understood. Inflammatory processes, HPA-axis func-
tion, and circadian rhythms are interrelated regulatory networks 
that communicate with each other through multiple signaling path-
ways, and all have been proposed as mechanisms underlying CRF 
(77–79). Understanding the biologic processes underlying CRF 
is critical to the identification of potential targets for therapeutic 
intervention. There is evidence of biologic dysregulation across 
cancer diagnoses and treatment modalities (80,81). However, due 
to a lack of systematic study of these potential confounding vari-
ables, it is not known if the mechanisms of symptom development 
and persistence differ by tumor and/or treatment type, although 
recent findings do not show substantial effects of treatment type in 
breast cancer survivors (47).
By far the most studied mechanism is the inflammatory process. 
Animal studies have shown that tissue damage or infection results in 
the release of proinflammatory cytokines that can signal the central 
nervous system, leading to a constellation of behavior changes 
known as “sickness behavior” (82–84). In humans, cytokines are 
released in response to cancer and/or its treatment resulting in self-
reported symptoms similar to animal sickness behaviors, of which 
fatigue is prominent. Findings from numerous studies over the past 
decade support an association between cytokine activity and fatigue, 
although results have been mixed (85–87). Research focused on 
pathways by which cytokines interact with neurocircuits in the 
brain have also been explored (88). Several studies have shown that 
inflammatory cytokines as well as inflammatory stimuli lead to 
changes in neural activity in the basal ganglia that in turn have been 
associated with symptoms of fatigue (89).
Upregulated cytokine signaling has been associated with other 
processes including HPA-axis dysfunction (89,90). In the nor-
mal physiologic environment, cortisol is released from the adre-
nal glands in a circadian pattern. One of its functions is to inhibit 
proinflammatory cytokine production and activity during acute 
stressful events (91). During chronic exposure to proinflammatory 
cytokines (as may occur in cancer and cancer therapies), the sen-
sitivity of the HPA axis is thought to be blunted; this decrease in 
cortisol production has been associated with CRF (91,92).
Circadian rhythms are the regular daily cycles of activity and 
rest controlled by the suprachiasmatic nucleus in the brain. Robust 
synchronized circadian rhythms are important to health and well-
being (78,93). HPA axis dysfunction and inflammation have been 
associated with disruption of circadian rhythms (94) and result 
in symptoms such as fatigue, sleep disturbance, and depression. 
Disrupted circadian rhythms have also been associated with mor-
tality in older men and women, dementia, and cancer (95–99). 
Emerging evidence suggests that individuals with CRF have dys-
regulated circadian activity/rest and sleep/wake rhythms including 
less daytime activity, later sleep onset at night, and more frequent 
awakening (53,93,100,101). CRF that worsens during chemother-
apy has also been associated with progressively worse and more 
enduring impairment of circadian activity rhythm (46).
Recent investigations have focused on genetic influences on 
symptoms including CRF. Technological advances and completion 
of the mapping of the human genome have enabled the develop-
ment of new tools for scanning the entire genome or examining 
candidate genes that could control the development and persistence 
of CRF. Several investigations have identified gene polymorphisms 
or variants that characterize individual differences in the severity of 
CRF (44). Most of this work on the genetics of CRF has focused 
primarily on genes involved in inflammatory pathways (102,103). 
Other research has focused on gene expression as an explanation of 
underlying mechanisms because expression involves not only the 
heritable aspects (gene variants) but also alterations due to environ-
mental changes (41,104,105). The study of gene polymorphisms 
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and gene expression has the potential to yield important infor-
mation about the mechanisms that control CRF including onset, 
persistence, and resolution (106). However, it would require large 
study samples.
recommendations
 • Conduct longitudinal research to examine the interrelated 
biobehavioral mechanisms underlying CRF.
 • Test mechanistic hypotheses within the context of CRF inter-
vention research.
 • Test new hypotheses about CRF mechanisms in animal models 
that control for the specific effects of tumor and treatment.
Interventions for Cancer-related Fatigue
Nonpharmacologic Interventions
The research literature on nonpharmacologic intervention for 
CRF is substantial encompassing several broad categories of psy-
chosocial therapies and physical activity. Three meta-analyses 
showed that psychosocial interventions had a small to moderate 
effect on CRF (5,7,8). However, psychosocial therapies comprise a 
diverse set of educational, supportive, and behavioral interventions, 
so conclusions cannot be drawn about the benefit of specific com-
ponents (8,107). To date, numerous meta-analyses have shown that 
exercise intervention had a statistically significant effect on CRF 
with magnitudes in the small to moderate range (3–5,8,9,11,108–
110). Exercise with aerobic and strength training components (150 
minutes per week of moderate to strenuous intensity activity and 
two to three weekly sessions focused on major muscle groups, 
respectively) was found to be more effective in reducing CRF than 
aerobic exercise alone (4), and supervised exercise was found to be 
more effective than home-based exercise (4). Recent studies have 
also demonstrated the benefit of physical activity for individuals 
with advanced cancer (111,112). Most research on the mechanisms 
underlying the benefit of exercise for cancer patients and survivors 
is derived from research in healthy populations (113,114). A  few 
studies have examined inflammatory changes or insulin resistance 
related to exercise in cancer survivors but not in connection with 
CRF (115–119).
The wealth of positive meta-analysis results for psychosocial 
and exercise interventions suggest the need for further research 
aimed to increase the effect size of beneficial interventions as well 
as dissemination studies to evaluate beneficial interventions such 
as exercise in community settings. Future studies should address 
motivational factors and barriers to implementation of exercise 
and psychosocial interventions as well as adherence (120,121). 
The patient advocates who participated in the CTPM recom-
mended the conduct of exercise intervention trials for survivors 
that are practical and exportable, addressing safety issues, appro-
priate regimens for different climates, and motivation as a key fac-
tor related to uptake of the intervention. Based on the evidence, 
the American College of Sports Medicine has published extensive 
exercise guidelines for different types of cancer that have implica-
tions for CRF (122).
There are many remaining questions about nonpharmacologic 
interventions that would be worthy of pursuit including yoga 
(123–125), mindfulness-based stress reduction (126,127), cognitive 
behavioral therapy for insomnia (128–133), and light treatment for 
prevention of CRF (134). In the current climate of personalized 
medicine, there may be a place for trials of tailored interventions 
powered for subgroup analysis with regard to efficacy for different 
groups based on demographic, medical, nutritional, and functional 
status. The ability to conduct large nonpharmacologic intervention 
trials would require additional resources. Nonpharmacologic 
interventions are generally labor intensive, and the intervention 
often requires delivery by staff with specialized training. 
Investigators may also consider more efficient use of resources by 
conducting telephone- and/or Internet-based intervention studies.
Pharmacologic Interventions for Cancer-Related Fatigue
In contrast to the sizable amount of research on nonpharmaco-
logic interventions for CRF, the pool of studies of pharmacologic 
interventions is much smaller and based largely on benefit in 
other diseases (such as multiple sclerosis) or conditions (such as 
advanced cancer). There has been only one systematic review and 
meta- analysis of 27 randomized controlled trials of pharmacologic 
treatment for CRF (135). The analysis was done by drug type, and 
the overall effect size for all drug classes was small. Based on two 
studies, methylphenidate, a sympathomimetic psychostimulant, was 
shown to be more effective than placebo. The antidepressant parox-
etine was evaluated in two trials, but no CRF benefit was observed. 
Three studies examined progestational steroids, but no CRF benefit 
was found. Although 10 studies of erythropoietin in anemic can-
cer patients undergoing chemotherapy found that it was superior 
to placebo and four trials of darbepoetin demonstrated superiority, 
current concerns about cardiovascular safety and reduced disease 
control suggest that these drugs should be used with caution for the 
management of CRF associated with anemia (136,137).
Another wakefulness-promoting agent, modafinil, was evaluated 
in one randomized controlled trial (138). The trial was negative 
overall; in secondary analysis, modafinil was found to be effective 
for individuals presenting with severe fatigue, suggesting the need 
for further evaluation of this drug. Another drug with potential 
for CRF management is bupropion, a norepinephrine dopamine 
 reuptake inhibitor, with favorable results in two open-label trials 
(139). Nonsteroidal antiinflammatory drugs and other drugs with 
direct and indirect cytokine antagonistic effects should also be 
 considered for future intervention trials.
Overall, advancement of the science of CRF management 
requires new approaches to the study of both nonpharmacologic 
and pharmacologic interventions. First, most previous research has 
lacked a theoretical framework and hypothesis testing about the 
potential biopsychosocial mechanisms underlying CRF. Moving for-
ward, it is imperative that intervention efficacy research be coupled 
with examination of hypotheses about the mechanisms by which 
interventions achieve their effects. Second, the strength of evidence 
in favor of physical activity intervention (including aerobic and 
strength- building components) suggests that dissemination research 
is in order. Future studies need to focus on overcoming barriers to 
implementation in the community setting and strategies to increase 
uptake and effect size of physical activity interventions. Third, given 
the strong likelihood of the placebo effect related to interventions 
for CRF, placebo-controlled studies are critical to the demonstration 
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of efficacy and remain the gold standard (140). Fourth, there is great 
potential for synergy between nonpharmacologic and pharmacologic 
interventions that should be exploited to enhance the effect size of 
interventions. Fifth, CRF is a heterogeneous condition that is likely 
to be affected by demographic, medical, nutritional, and functional 
status. Careful consideration needs to be given to eligibility for par-
ticipation in clinical trials of CRF management to minimize hetero-
geneity. Moreover, consideration needs to be given to the severity of 
CRF as an eligibility criterion because at least one study found that 
efficacy of a drug intervention was limited to individuals with severe 
fatigue (138), and most previous intervention trials did not have a spe-
cific inclusion criterion limiting eligibility to fatigued individuals (8).
recommendations
 • Conduct research with randomized placebo-controlled trial 
designs, and consider the use of recently developed strategies 
such as the doubly randomized preference trials.
 • Carefully consider eligibility for CRF intervention trials to min-
imize sample heterogeneity or enable subgroup analysis.
 • Establish a threshold of symptom severity for participation in 
CRF clinical trials.
 • Conduct dissemination trials of efficacious interventions (such 
as exercise) focused on overcoming barriers to implementation 
and strategies to increase uptake and effect size of interventions.
 • Combine nonpharmacologic and pharmacologic interventions 
to exploit the potential synergy between these two approaches.
Summary
Although much has been accomplished over the past decades, there 
is a need to focus future research in critical directions to advance 
the science of CRF management. This commentary reports the 
recommendations of participants in a National Cancer Institute 
CTPM and an ongoing National Cancer Institute working group 
for high-priority clinical trial investigations of CRF over the next 
several years. Three areas of science have been addressed in this 
commentary: measurement, biology, and intervention for CRF. 
Implementation of these recommendations has the potential to 
1)  advance our understanding of the biobehavioral mechanisms 
of CRF; 2)  identify new targets for intervention to prevent or 
treat CRF; 3)  accomplish the dissemination of efficacious inter-
ventions into the community; and 4)  leverage the yield beyond 
individual studies by pooling and comparing data across studies. 
Accomplishing these goals will advance the science of CRF and 
improve the clinical management of this troubling symptom.
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